Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions (NOVA)

  • End date
    Apr 30, 2024
  • participants needed
  • sponsor
    Nemours Children's Clinic
Updated on 10 April 2023


Proposed Study: Treatment protocol for the use of the topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and other susceptible lesions

  1. Aim The aim of this treatment study is to evaluate the benefit and tolerability of topical sirolimus applied to cutaneous vascular anomalies in pediatric patients. The primary end point will be individually determined based on improvement in lesional clinical characteristics over baseline
  2. Rationale for topical sirolimus use in VA The rationale for the use of topical sirolimus is to minimize these potential side effects and risks. Data for the use of topical sirolimus for vascular anomalies at this time are anecdotal and case reports only. As such, this prospective protocol seeks to determine the effectiveness and tolerability of topical sirolimus on patients with vascular anomalies that have a cutaneous component.
  3. Experimental design This is an open-labeled efficacy trial with the aim to determine if topical sirolimus can be safe and efficacious in treating the cutaneous component of complicated vascular anomalies. Patients who meet eligibility criteria with a diagnosis of vascular anomaly (VA) with cutaneous component will be offered treatment with the investigational topical sirolimus. Patients will receive topical sirolimus therapy for a total of six months and will be monitored regularly at the research site for clinical response. Response will be based on pre-determined clinical criteria. Patients will be removed from study if there is no response at three months after initiation of therapy.

Clinical response will be defined as improvement in measurable parameters defined at the time of initiation of therapy. These include

  1. Size of lesions, measured in two parallel longest diameters
  2. Flattening of lesion
  3. Number of vesicles
  4. Episodes of superinfection or bleeding
  5. Improvement in pain
  6. Drug Information The topical sirolimus formulation will be made at a concentration of 1% sirolimus ointment. Bulk sirolimus powder will be compounded in a liposomal base in a GMP level pharmaceutical company. This base will enhance drug penetration into the skin. It ensures adequate adhesion to the application area and a low degree of systemic absorption. Due to limited absorption only mild side effects are expected.


Patients with vascular anomalies (VA) have a spectrum of diseases that can be broadly classified into vascular tumors and malformations. Complicated vascular anomalies can cause disfigurement, chronic pain, and organ dysfunction with significant morbidity and mortality. Despite the severity of potential complications, we lack uniform guidelines for the treatment and response to treatment of children and young adults with these diseases. Pre-clinical and clinical data supporting the essential regulatory function of the PI3K/Akt/mTOR pathway in vascular growth and organization, and suggest a therapeutic target for patients with complicated vascular anomalies. Nemours Children's Hospital (NCH) and other groups have been successfully using the mTOR inhibitor siroli-mus in a selected group of patients with VA. NCH exclusively uses the systemic oral formulation of sirolimus. The potential toxicities of systemic sirolimus is well documented, and many patients do not tolerate systemic sirolimus. We hypothesize this study will advance our treatment options of vascular anomalies by offering topical sirolimus. This prospective open labeled study will allow us to determine the efficacy and tolerability of topical sirolimus in the treatment of complicated vascular anomalies. This will potentially generate data for the use of topical sirolimus as an alternative to systemic sirolimus for patients with complicated VA with a cutaneous component.

Condition Vascular Anomaly
Treatment Topical Sirolimus
Clinical Study IdentifierNCT04172922
SponsorNemours Children's Clinic
Last Modified on10 April 2023


Yes No Not Sure

Inclusion Criteria

Patients will be more than 36 months and less than 21 years of age
Newly diagnosed with vascular anomalies (VA) or have a VA that failed therapy with systemic sirolimus or other systemic or surgical therapies
Patients who have undergone surgical resection or interventional radiology procedures for disease control are eligible to start topical sirolimus
At least 2 weeks since undergoing any major surgery
Must not have received Myelosuppressive chemotherapy within 4 weeks of starting sirolimus
At least 7 days since the completion of therapy with a GF that supports platelet, red or white cell number or function
At least 14 days since the completion of therapy with a biologic agent
Patients with Kaposiform Hemagioendothelioma who have failed or are intolerant of systemic sirolimus therapy
Patients must not have received any non-FDA approved drug within 4 weeks or 5 half-lives, whichever is longer, prior to starting sirolimus and during treatment with sirolimus
XRT: > or = 6 months from involved field radiation to vascular tumor
Patients may not be currently receiving strong inhibitors of CYP3A4 and may not have received medications within 1 week of starting sirolimus
Patients may not be taking enzyme-inducing anticonvulsants, and may not have received these medications within 1 week of starting topical sirolimus, as these patients may experience different drug disposition
Adequate organ function
Total bilirubin ≤1.5 x ULN for age
SGPT (ALT) <5 x ULN for age
Serum albumin > or = 2 g/dL
Fasting LDL cholesterol of <160 mg/dL
Adequate Bone Marrow Function
Hemoglobin > or = 8.0 gm/dL (may receive RBC transfusions)
Platelet count > or = 50,000/microL (transfusion independent defined as not receiving a platelet transfusion within a 7 day period prior to sirolimus use)
Adequate Renal Function
A serum creatinine based on age
Urine protein to creatinine ratio (UPC) < 0.3 g/l
Karnofsky > or = 50 (>/=16 years of age) and Lansky >/ = 50 for patients < 16 years of age

Exclusion Criteria

Concurrent severe and/or uncontrolled medical disease which could compromise compliance with safety monitoring requirements for sirolimus (e.g. uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration)
Chronic treatment with systemic steroids or another immunosuppressive agent
Patients who require medications that inhibit/induce CYP3A4 enzyme activity to control concurrent medical conditions
Known history of HIV seropositivity or known immunodeficiency
Women who are pregnant or breast feeding
Males or females of reproductive potential should agree to use an effective contraceptive method during the period they are receiving topical sirolimus and for 3 months thereafter
Patients unwilling or unable to comply with the safety monitoring requirements for sirolimus
Patients who currently have an uncontrolled infection, defined as receiving intravenous antibiotics
Patients with hemangioma
Patients with symptomatic complicated vascular anomalies with severe systemic symptoms that will need systemic therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note